{
    "root": "73da5bae-dfd7-4081-b32a-8cbc3c116d97",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "FINGOLIMOD"
    },
    "value": "20250301",
    "ingredients": [
        {
            "name": "FINGOLIMOD HYDROCHLORIDE",
            "code": "G926EC510T"
        },
        {
            "name": "MALTODEXTRIN",
            "code": "7CVR7L4A2D"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        }
    ],
    "indications": "fingolimod capsules indicated treatment relapsing forms multiple sclerosis ( multiple sclerosis ) , include clinically isolated syndrome , relapsing-remitting disease , active secondary progressive disease , patients 10 years age older .",
    "contraindications": "assessments required prior initiating fingolimod capsules . ( 2.1 ) recommended adults pediatric patients ( 10 years age older ) weighing 40 kg : 0.5 mg orally daily , without food . ( 2.2 , 2.3 ) first-dose monitoring ( including reinitiation discontinuation greater 14 days dose increases ) : observe patients bradycardia least 6 hours ; monitor pulse blood pressure hourly . electrocardiograms ( ecgs ) prior dosing end observation period required . ( 2.4 ) monitor resolution heart rate < 45 beats per minute ( bpm ) adults , < 55 bpm patients aged 12 years , < 60 bpm pediatric patients aged 10 12 years , atrioventricular ( av ) block , lowest postdose heart rate end observation period . ( 2.4 ) monitor symptomatic bradycardia ecg resolved . continue overnight intervention required ; repeat first-dose monitoring second dose . ( 2.4 ) observe patients overnight higher risk symptomatic bradycardia , heart block , prolonged qtc interval , taking drugs known risk torsades de pointes . ( 2.4 , 7.1 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "fingolimod capsules contraindicated patients : last 6 months experienced myocardial infarction , unstable angina , stroke , transient ischemic attack ( tia ) , decompensated heart failure requiring hospitalization class iii/iv heart failure history presence mobitz type ii second-degree third-degree av block sick sinus syndrome , unless patient functioning pacemaker [ ( 5.1 ) ] baseline qtc interval ≥ 500 msec cardiac arrhythmias requiring anti-arrhythmic treatment class ia class iii anti-arrhythmic drugs hypersensitivity reaction fingolimod excipients fingolimod capsules . observed include rash , urticaria angioedema upon treatment initiation [ ( 5.14 ) ] .",
    "indications_original": "Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.",
    "contraindications_original": "Assessments are required prior to initiating fingolimod capsules. ( 2.1 ) Recommended dosage for adults and pediatric patients (10 years of age and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food. ( 2.2, 2.3 ) First-Dose Monitoring (including reinitiation after discontinuation greater than 14 days and dose increases): Observe all patients for bradycardia for at least 6 hours; monitor pulse and blood pressure hourly. Electrocardiograms (ECGs) prior to dosing and at end of observation period required. ( 2.4 ) Monitor until resolution if heart rate < 45 beats per minute (bpm) in adults, < 55 bpm in patients aged 12 years and above, or < 60 bpm in pediatric patients aged 10 to below 12 years, atrioventricular (AV) block, or if lowest postdose heart rate is at the end of the observation period. ( 2.4 ) Monitor symptomatic bradycardia with ECG until resolved. Continue overnight if intervention is required; repeat first-dose monitoring for second dose. ( 2.4 ) Observe patients overnight if at higher risk of symptomatic bradycardia, heart block, prolonged QTc interval, or if taking drugs with known risk of torsades de pointes. ( 2.4, 7.1 )",
    "adverseReactions_original": "Fingolimod capsules are contraindicated in patients who have:\n                  \n                     in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization or Class III/IV heart failure\n                     a history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker [see Warnings and Precautions (5.1)]\n                     \n                     a baseline QTc interval ≥ 500 msec\n                     cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs\n                     had a hypersensitivity reaction to fingolimod or any of the excipients in fingolimod capsules. Observed reactions include rash, urticaria and angioedema upon treatment initiation [see Warnings and Precautions (5.14)]."
}